Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 3

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 245Lymphoid 240Myeloid 65Sarcoma 39Breast 38Plasma cell 29Classical hematology 26CNS 19Dermatologic 16Genitourinary 15Head & Neck 9Gynecologic 4Tumor-Agnostic 3Thoracic 3Other neoplasm 3Other solid neoplasm 2Other 2Gastrointestinal 1

Conditions

Neoplasms 2Carcinoma 1

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 32Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Methotrexate × Tumor-Agnostic × Clear all
NCT02412670 2023-07-10

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

Eastern Cooperative Oncology Group

Phase 2 Completed
36 enrolled 14 charts
Tumor-Agnostic

Carcinoma

NCT02076997 2021-02-24

Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate

Baylor College of Medicine

Phase NA Completed
23 enrolled 11 charts
Tumor-Agnostic

Neoplasms

NCT01031420 2019-09-17

Dose Dense MVAC for Muscle Invasive Bladder Cancer

Fox Chase Cancer Center

Phase 2 Completed
54 enrolled 7 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡